EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Brain-specific glycosylation enzyme GnT-IX maintains levels of protein tyrosine phosphatase receptor PTPRZ, thereby mediating glioma growth

Kenichiro Nagai, Yui Muto, Saori Miura, Kazuto Takahashi, Yu Naruse, Ryo Hiruta, Yuko Hashimoto, Miwa Uzuki, Yoshimi Haga, Risa Fujii, Koji Ueda, Yasushi Kawaguchi und 2 weitere

Journal of Biological Chemistry · 2023

DOI: 10.1016/j.jbc.2023.105128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2023. Verfasst von Kenichiro Nagai und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Fukushima Medical University, Fukushima, Japan. Hauptthemen laut MEDLINE: Glioma, N-Acetylglucosaminyltransferases, Receptor-Like Protein Tyrosine Phosphatases, Class 5. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mizutani Foundation for Glycoscience, Japan Agency for Medical Research and Development, Gifu University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gliomas are the most prevalent primary tumor of the central nervous system. Despite advances in imaging technologies, neurosurgical techniques, and radiotherapy, a cure for high-grade glioma remains elusive. Several groups have reported that protein tyrosine phosphatase receptor type Z (PTPRZ) is highly expressed in glioblastoma, and that targeting PTPRZ attenuates tumor growth in mice. PTPRZ is modified with diverse glycan, including the PTPRZ-unique human natural killer-1 capped O-mannosyl core M2 glycans. However, the regulation and function of these unique glycans are unclear. Using CRISPR genome-editing technology, we first demonstrated that disruption of the PTPRZ gene in human glioma LN-229 cells resulted in profoundly reduced tumor growth in xenografted mice, confirming the potential of PTPRZ as a therapeutic target for glioma. Furthermore, multiple glycan analyses revealed that PTPRZ derived from glioma patients and from xenografted glioma expressed abundant levels of human natural killer-1-capped O-Man glycans via extrinsic signals. Finally, since deficiency of O-Man core M2 branching enzyme N-acetylglucosaminyltransferase IX (GnT-IX) was reported to reduce PTPRZ protein levels, we disrupted the GnT-IX gene in LN-229 cells and found a significant reduction of glioma growth both in vitro and in the xenograft model. These results suggest that the PTPR glycosylation enzyme GnT-IX may represent a promising therapeutic target for glioma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaN-AcetylglucosaminyltransferasesReceptor-Like Protein Tyrosine Phosphatases, Class 5AnimalsHumansMiceBrainPolysaccharidesCell Line, TumorFemaleMice, SCIDGene Knockdown TechniquesNerve Tissue Proteins

Stichwörter der Autor:innen

GnT-IXHNK-1O-Man glycanPTPRZgliomaglycosylationtherapeutic target

Substanzen

N-AcetylglucosaminyltransferasesPolysaccharidesReceptor-Like Protein Tyrosine Phosphatases, Class 5MGAT5B protein, humanNerve Tissue ProteinsN-acetylglucosaminyltransferase IX, mouse

Autor:innen und Institutionen

  • Department of Neurosurgery, Fukushima Medical University, Fukushima, Japan.
  • Division of Molecular Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Department of Clinical Laboratory Sciences, School of Health Sciences, Fukushima Medical University, Fukushima, Japan.
  • Department of Diagnostic Pathology, Fukushima Medical University, Fukushima, Japan.
  • Cancer Proteomics Group, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Division of Molecular Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Infectious Disease Control, International Research Center…

Förderung

  • Mizutani Foundation for Glycoscience
  • Japan Agency for Medical Research and Development
  • Gifu University
  • University of Tokyo
  • AMED Collaborative Research Based on Industrial Demand

Zitieren

APA

Nagai, K., Muto, Y., Miura, S., Takahashi, K., Naruse, Y., Hiruta, R., Hashimoto, Y., Uzuki, M., Haga, Y., Fujii, R., Ueda, K., Kawaguchi, Y., Fujii, M., & Kitazume, S. (2023). Brain-specific glycosylation enzyme GnT-IX maintains levels of protein tyrosine phosphatase receptor PTPRZ, thereby mediating glioma growth. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2023.105128

Vancouver

Nagai K, Muto Y, Miura S, Takahashi K, Naruse Y, Hiruta R, et al. Brain-specific glycosylation enzyme GnT-IX maintains levels of protein tyrosine phosphatase receptor PTPRZ, thereby mediating glioma growth. Journal of Biological Chemistry. 2023. doi:10.1016/j.jbc.2023.105128

BibTeX
@article{Nagai2023,
  author = {Nagai, Kenichiro and Muto, Yui and Miura, Saori and Takahashi, Kazuto and Naruse, Yu and Hiruta, Ryo and Hashimoto, Yuko and Uzuki, Miwa and Haga, Yoshimi and Fujii, Risa and Ueda, Koji and Kawaguchi, Yasushi and Fujii, Masazumi and Kitazume, Shinobu},
  title = {Brain-specific glycosylation enzyme GnT-IX maintains levels of protein tyrosine phosphatase receptor PTPRZ, thereby mediating glioma growth},
  journal = {Journal of Biological Chemistry},
  year = {2023},
  doi = {10.1016/j.jbc.2023.105128}
}
Kostenlos starten →